Ces radiol. 2016, 70(4):205-218 | DOI: 10.55095/CesRadiol2016/028

Lessons in molecular imaging: the assessment of brain tumors using PET/MRIReview article

Jiří Ferda1, Eva Ferdová1, Jan Baxa1, Radek Tupý1, Ondřej Hes2, Jan Mraček3
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Šiklův ústav patologické anatomie LF UK a FN, Plzeň
3 Neurochirurgická klinika LF UK a FN, Plzeň

The combined imaging of morphology, microstructure and function provides comprehensive information about behavior of the brain tissue. Diffusion weighted imaging is important in the evaluation of cellularity, spectroscopy provides the in vivo metabolite analysis related to the biomembrane building or destruction supplemented by the information about anaerobic glycolysis in hypoxic state of the tumor. Metabolic imaging using PET are able to assess the entire tumor extent (18F-FET, 18F-FDOPA, 18F-FCH), or to assess the grade of dedifferentiation (18F-FDG, 18F-FLT, 18F-FDOPA, 18F-FET). Multiparametric analysis of the tissue characteristic and derived information about tumor phenotype is natural advantage of PET/MRI.

Keywords: PET/MRI, brain tumors, fluorodeoxyglucose, fluorothymidin, fluroetyltyrosine, fluorodihydroxyphenylalanine
Grants and funding:

Podpořeno projektem Ministerstva zdravotnictví ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).

Accepted: December 15, 2016; Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Ferdová E, Baxa J, Tupý R, Hes O, Mraček J. Lessons in molecular imaging: the assessment of brain tumors using PET/MRI. Ces radiol. 2016;70(4):205-218. doi: 10.55095/CesRadiol2016/028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wang S, Kim S, Chawla S, et al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011; 32(3): 507-514. Go to original source... Go to PubMed...
    2. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7(1): 91-101. Go to original source... Go to PubMed...
    3. Yao NW, Chang C, Lin HT, Yen CT, Chen JY. Functional assessment of glioma pathogenesis by in vivo multi-parametric magnetic resonance imaging and in vitro analyses. Sci Rep 2016; 20(6): 26050. doi:10.1038/srep26050. PubMed PMID: 27198662 Go to original source... Go to PubMed...
    4. Gadda D, Mazzoni LN, Pasquini L, et al. Relationship between apparent diffusion coefficients and mr spectroscopy findings in high-grade gliomas. J Neuroimaging 2016; doi: 10.1111/jon.12350. PubMed PMID: 27079293. Go to original source... Go to PubMed...
    5. Nagashima H, Tanaka K, Sasayama T, et al. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Neuro Oncol 2016; 18(11): 1559-1568. Go to original source... Go to PubMed...
    6. Dankbaar JW, Snijders TJ, Robe PA, Seute T, et al. The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. J Neurooncol 2015; 125(1): 167-175. Go to original source... Go to PubMed...
    7. Lam WW, Ng DC, Wong WY, Ong SC, Yu SW, See SJ. Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors-early experience. Clin Neurol Neurosurg 2011; 13(2): 156-161. Go to original source... Go to PubMed...
    8. Ferdová E, Ferda J, Baxa J, Tupý R, Mraček J, Topolčan O, Hes O. Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT. Anticancer Res 2015; 35(2): 955-959.
    9. Collet S, Valable S, Constans JM et al. [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. Neuroimage Clin 2015; 29: 448-454. Go to original source... Go to PubMed...
    10. Nowosielski M, DiFranco MD, Putzer D, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS One 2014; 9(4): e95830. doi:10.1371/journal.pone.0095830. PubMed PMID: 24759867 Go to original source... Go to PubMed...
    11. Jena A, Taneja S, Gambhir A, Mishra AK, D'souza MM, Verma SM, Hazari PP, Negi P, Jhadav GK, Sogani SK. Glioma recurrence versus radiation necrosis: single-session multiparametric approach using simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI. Clin Nucl Med 2016; 41(5): e228-222. Go to original source... Go to PubMed...
    12. Unterrainer M, Schweisthal F, Suchorska B, Wenter V, Schmid-Tannwald C, Fendler WP, Schüller U, Bartenstein P, Tonn JC, Albert NL. Serial 18F-FET PET imaging of primarily 18F-FET-negative glioma: Does it make sense? J Nucl Med 2016; 57(8): 1177-1182. doi:10.2967/jnumed.115.171033. PubMed PMID: 27033893. Go to original source... Go to PubMed...
    13. Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, Todica A, Brendel M, Tonn JC, Bartenstein P, la Fougère C. Early static (18) F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans. Eur J Nucl Med Mol Imaging 2016; 43(6): 1105-1114. Go to original source... Go to PubMed...
    14. Bette S, Peschke P, Kaesmacher J, Delbridge C, Pyka T, Schmidt-Graf F, Zimmer C, Meyer B, Ringel F, Gempt J. Static FET-PET and MR imaging in anaplastic gliomas (WHO III). World Neurosurg 2016; 91: 524-531.e1. doi:10.1016/j.wneu.2016.02.094. PubMed PMID: 26947726 Go to original source... Go to PubMed...
    15. Moller S, Law I, Munck Af Rosenschold P, Costa J, Poulsen HS, Engelholm SA, Engelholm S. Prognostic value of (18) F-FET PET imaging in re-irradiation of high-grade glioma: Results of a phase I clinical trial. Radiother Oncol 2016; 121(1): 132-137. Go to original source... Go to PubMed...
    16. Cicuendez M, Lorenzo-Bosquet C, Cuberas-Borrós G, Martinez-Ricarte F, Cordero E, Martinez-Saez E, Castell-Conesa J, Sahuquillo J. Role of [(11) C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clin Neurol Neurosurg 2015; 139? 328-333. Go to original source... Go to PubMed...
    17. Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, Smith J, Rose S. Increasing feasibility and utility of (18) F-FDOPA PET for the management of glioma. Nucl Med Biol 2015; 42(10): 788-795. Go to original source... Go to PubMed...
    18. Villani V, Carapella CM, Chiaravalloti A, Terrenato I, Piludu F, Vidiri A, Schillaci O, Floris R, Marzi S, Fabi A, Pace A. The role of PET [18F]FDOPA in evaluating low-grade glioma. Anticancer Res 2015; 35(9): 5117-5122.
    19. Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal S, Kumar R, Kumar R, Bal C. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study. Eur J Radiol 2014; 83(1): 219-225. Go to original source... Go to PubMed...
    20. Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship between [18F]FDOPA PET uptake, apparent diffusion coefficient (ADC), and proliferation rate in recurrent malignant gliomas. Mol Imaging Biol 2015; 17(3): 434-442. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content